1. 1) Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J. Clin., 66, 115–132 (2016).
2. 2) Stahl M, Budach W, Meyer HJ, Cervantes A. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 21 (Suppl. 5), v46–v49 (2010).
3. 3) Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth. Analg., 110, 1636–1643 (2010).
4. 4) Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Lim H, Kim SE, Eom W. Association of high-dose postoperative opioids with recurrence risk in esophageal squamous cell carcinoma: reinterpreting ERAS protocols for long-term oncologic surgery outcomes. Dis. Esophagus, 30, 1–8 (2017).
5. 5) Kelly E. Efficacy and ligand bias at the mu-opioid receptor. Br. J. Pharmacol., 169, 1430–1446 (2013).